Bookmark

Add to MyYahoo RSS

Bloomsbury Publishing News

News on Bloomsbury Publishing (Ticker: BMY) continually updated from thousands of sources around the net.

8 hrs ago | Seeking Alpha

Bristol-Myers Squibb: Great Dividend Stocks From The Bond Refugee...

BMY stock is expensive,on a relative basis, to the S&P 500 and healthcare sector earnings multiples and projected five year growth rates.

Comment?

Related Topix: Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Financial Markets, Biotech, Medicine, Healthcare Industry

Tue Apr 22, 2014

Business Wire

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Financial terms of the agreement are not disclosed. Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals

POZ

BMS Files for FDA Approval of Reyataz/Cobicistat Combo Pill

Bristol-Myers Squibb has filed a new drug application with the U.S. Food and Drug Administration for a fixed-dose combination tablet of Reyataz and cobicistat for the treatment of HIV.

Comment?

Related Topix: Reyataz, Atazanavir Sulfate (generic), Healthcare Law, Food and Drug Administration, Law, Biotech, Bristol Myers Squibb, Publishing, Media, Medicine, Pharmaceuticals, Healthcare Industry

Thu Apr 17, 2014

P&T Community

New Drug Application Submitted to FDA for Fixed-Dose Atazanavir/Cobicistat Combo for HIV-1 Patients

A new drug application has been submitted to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz , and cobicistat , an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain human immunodeficiency virus-1 medications in the blood and make them more ... (more)

Comment?

Related Topix: Health, HIV/AIDS, Reyataz, Atazanavir Sulfate (generic), Law, Healthcare Law, Bristol Myers Squibb, Biotech, Media, Publishing, Medicine, Pharmaceuticals, Healthcare Industry

Wed Apr 16, 2014

Hispanic Business

Bristol-Myers Squibb Presents Phase III Data Demonstrating that...

Results showed that the 24-week regimen achieved an overall sustained virologic response 12 weeks after the end of treatment among treatment-naive , peginterferon/ribavirin non-responder , and peginterferon/ribavirin ineligible/intolerant patients, including cirrhotic and non-cirrhotic patients .

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Healthcare Industry, Hepatitis

Tue Apr 15, 2014

The Motley Fool

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Does Merck stand a chance? Merck has lagged the hepatitis C race, but the phase 2 results from its oral combination of MK-5172 and MK-8742 in genotype 1 patients are quite impressive.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals

Reuters

UPDATE 1-Boehringer 2013 profit up on Pradaxa sales, cost cuts

German drugmaker Boehringer Ingelheim's operating income rose 14 percent last year as cost cuts and sales of anti-blood-clotting drug Pradaxa helped counter the impact of currency effects, it said on Tuesday.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry

Mon Apr 14, 2014

Pharmaceutical Processing

BMS Submits NDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for HIV-1

Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz , and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the ... (more)

Comment?

Related Topix: Reyataz, Atazanavir Sulfate (generic), Health, HIV/AIDS, Bristol Myers Squibb, Biotech, Medicine, Healthcare Industry, Law, Healthcare Law, Media, Publishing, Pharmaceuticals

Sat Apr 12, 2014

MediaPost

Bristol-Myers Squibb, FCB Sue Omnicom, Schulman Over Trade Secrets

A nasty court fight is taking shape in New York between Interpublic's FCB and its client Bristol-Myers Squibb on one side and a former FCB account manager, Stephanie Shulman and Omnicom Group on the other.

Comment?

Related Topix: Omnicom Group, Advertising, DDB Worldwide Communications Group, Biotech, Bristol Myers Squibb, Publishing, Media, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry

Fri Apr 11, 2014

The Toronto Star

Denied experimental drug, cancer patient pins hope on new clinical trial

If that doesn't work, Adrienne Lotton may travel to the U.S. to try a similar drug released for compassionate use.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry

Thu Apr 10, 2014

Information Technology

Bristol-Myers Squibb Presents Phase III Data Demonstrating that...

Bristol-Myers Squibb Company today announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir , a NS5A inhibitor, and asunaprevir , a NS3 inhibitor, among genotype 1b hepatitis C virus infected patients.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Hepatitis, Health, Food and Drug Administration, Marketing

Tue Apr 08, 2014

Contract Pharma Breaking News

DKSH, BMS Extend Asia-Pac Partnership

DKSH , a market expansion services provider with a focus on Asia, has extended its partnership with Bristol-Myers Squibb to provide commercial and distribution services in Asia covering six markets: Hong Kong, Malaysia, Singapore, Taiwan, Thailand and Vietnam.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry, Marketing

Mon Apr 07, 2014

BioSpace

Bristol-Myers Squibb Company Submits NDAs For Daclatasvir And...

Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C U.S. application submission marks third major daclatasvir regulatory milestone globally, follows E.U. and Japan PRINCETON, N.J.--April 07, 2014-- Bristol-Myers Squibb Company announced today that they have submitted new drug applications ... (more)

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Bristol-Myers Squibb, Hepatitis, Food and Drug Administration, Health

Tue Apr 01, 2014

Freshnews

Bristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29

Bristol-Myers Squibb Company will announce results for the first quarter of 2014 on Tuesday, April 29, 2014.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals

Mon Mar 31, 2014

The Lebanon Daily News

LVC professor's book studies the impact of digital art

Lebanon Valley College associate professor of art history Dr. Grant Taylor will officially release his latest book, "When the Machine Made Art," through Bloomsbury Publishing on April 10. The book represents four years of work and development, as well as a number of years of research in this field.

Comment?

Related Topix: Lebanon Valley College, Publishing, Media

Thu Mar 27, 2014

Seeking Alpha

A Look Back At Big Pharma Stocks

Four years ago, I wrote about what I called "Big Pharma's Lost Decade" in the stock market.

Comment?

Related Topix: Financial Markets, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry

Examiner.com

Paltrow's 'conscious uncoupling' after 10 years of 'conscious coupling'

Gwyneth Paltrow attends Hollywood Stands Up To Cancer Event with contributors American Cancer Society and Bristol Myers Squibb on 1/28/14.

Comment?

Related Topix: Charitable Organizations, American Cancer Society, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry

The Motley Fool

Big Pharma's Not-So-Hidden Secret to Success

Organic pipeline innovation and acquisitions aside, this has been the biggest driver of Big Pharma's success in recent years.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Food and Drug Administration

Business Wire

In A Subanalysis, The Benefits Of Eliquis (apixaban) Vs. Warfarin In...

However, this subanalysis found consistent results for Eliquis versus warfarin in reducing the risk of stroke, regardless of blood pressure control.1 These data will be presented Saturday, March 29, at the American College of Cardiology's 63rd Annual Scientific Session in Washington, D.C. "High blood pressure is a risk factor for stroke in patients ... (more)

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Pfizer, Excaliard Pharmaceuticals, Publishing, Media, Medarex

Wed Mar 26, 2014

Hispanic Business

Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results

"2013 was a transformational year for Five Prime with many important milestones.

Comment?

Related Topix: Medicine, Cancer, Health, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••